Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
Impact in
- Hepatology 2.4k
- Epidemiology 631
Classified as
- Journal
- The Lancet
In The Last Decade
doi.org/10.1016/s0140-6736(02)08649-x →Countries where authors are citing Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
This map shows the geographic impact of Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial more than expected).
Fields of papers citing Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
This network shows the impact of Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
About Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
This paper, published in 2002, received 2.9k indexed citations . Written by Josep Maria Llovet, María Isabel Real, Xavier Montañá, Ramón Planas, S. Coll, Carmen Ayuso, Jordi Muchart, Ricard Solà, Joan Rodés and Jordi Bruix covering the research area of Hepatology. It is primarily cited by scholars working on Hepatology (2.4k citations), Epidemiology (631 citations), Surgery (388 citations), Pulmonary and Respiratory Medicine (301 citations) and Pathology and Forensic Medicine (257 citations). Published in The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1016/s0140-6736(02)08649-x.